

Constance Thibault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6741452/publications.pdf>

Version: 2024-02-01

35
papers

454
citations

840728

11
h-index

752679

20
g-index

37
all docs

37
docs citations

37
times ranked

995
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Features and management of men with pN1 cMO prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. <i>Current Opinion in Urology</i> , 2022, 32, 69-84. | 1.8 | 6 |
| 2 | Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 535-535. | 1.6 | 5 |
| 3 | Life-threatening skin reaction with Enfortumab Vedotin: Six cases. <i>European Journal of Cancer</i> , 2022, 167, 168-171. | 2.8 | 10 |
| 4 | Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. <i>Cancers</i> , 2022, 14, 1678. | 3.7 | 7 |
| 5 | Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancerâ€”Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147. | 3.7 | 2 |
| 6 | Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832. | 0.8 | 2 |
| 7 | Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751. | 3.1 | 19 |
| 8 | Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. <i>Oncolmmunology</i> , 2021, 10, 1888488. | 4.6 | 9 |
| 9 | Cabazitaxel multiple rechallenge in metastatic castration-resistant prostate cancer: A therapeutic option to increase overall survival?. <i>Journal of Clinical Oncology</i> , 2021, 39, 97-97. | 1.6 | 0 |
| 10 | Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO).. <i>Journal of Clinical Oncology</i> , 2021, 39, 330-330. | 1.6 | 2 |
| 11 | Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 671969. | 2.8 | 7 |
| 12 | How did we take care of our older cancer patients during the first COVID-19 wave? The French experience. <i>Bulletin Du Cancer</i> , 2021, 108, 589-595. | 1.6 | 1 |
| 13 | Emerging Targeted Therapy for Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 585-596. | 2.2 | 4 |
| 14 | Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data. <i>Cancer Treatment Reviews</i> , 2021, 97, 102191. | 7.7 | 17 |
| 15 | Response to systemic therapy in fumarate hydrataseâ€”deficient renal cell carcinoma. <i>European Journal of Cancer</i> , 2021, 151, 106-114. | 2.8 | 18 |
| 16 | Cabazitaxel multiple rechallenges in metastatic castrationâ€”resistant prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6304-6309. | 2.8 | 3 |
| 17 | A realâ€”world comparison of docetaxel versus abiraterone acetate for metastatic hormoneâ€”sensitive prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6354-6364. | 2.8 | 7 |
| 18 | Pharmaceutical consultation to detect drug interactions in patients treated with oral chemotherapies: A descriptive crossâ€”sectional study. <i>European Journal of Cancer Care</i> , 2021, 30, e13396. | 1.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Studying Rarity in Bladder Cancer. <i>European Urology</i> , 2020, 77, 447-448. | 1.9 | 0 |
| 20 | Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. <i>European Journal of Cancer</i> , 2020, 125, 153-163. | 2.8 | 5 |
| 21 | Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. <i>Bulletin Du Cancer</i> , 2020, 107, eS8-eS15. | 1.6 | 11 |
| 22 | BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. <i>Bulletin Du Cancer</i> , 2020, 107, eS22-eS27. | 1.6 | 37 |
| 23 | Evaluation of medical practices in oncology in the context of the COVID-19 pandemic in France: Physicians' point of view: the PRATICOVID study. <i>Cancer Medicine</i> , 2020, 9, 8875-8883. | 2.8 | 8 |
| 24 | Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097813. | 3.2 | 11 |
| 25 | Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1195-1203. | 0.9 | 6 |
| 26 | Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2018, 97, 41-48. | 2.8 | 9 |
| 27 | Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. <i>European Heart Journal</i> , 2018, 39, 3553. | 2.2 | 21 |
| 28 | Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 350-355. | 1.9 | 26 |
| 29 | Outcomes in elderly patients admitted to the intensive care unit with solid tumors. <i>Annals of Intensive Care</i> , 2017, 7, 26. | 4.6 | 40 |
| 30 | A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1058, 102-107. | 2.3 | 12 |
| 31 | Sunitinib in kidney cancer: 10 years of experience and development. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 129-142. | 2.4 | 30 |
| 32 | Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. <i>Translational Andrology and Urology</i> , 2017, 6, 1049-1059. | 1.4 | 3 |
| 33 | Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. <i>PLoS Medicine</i> , 2016, 13, e1002199. | 8.4 | 76 |
| 34 | Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. <i>Oncolimmunology</i> , 2015, 4, e1001236. | 4.6 | 22 |
| 35 | HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 123-133. | 4.4 | 16 |